Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody

References

• LarkinJChiarion-SileniVGonzalezRCombined nivolumab and ipilimumab or monotherapy in untreated melanomaN Engl J Med2015373233426027431
   PubMed Web of Science ®Google Scholar
• MullardANew checkpoint inhibitors ride the immunotherapy tsunamiNat Rev Drug Discov20131248949223812256
   PubMed Web of Science ®Google Scholar
• FifeBTPaukenKEEagarTNInteractions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signalNat Immunol2009101185119219783989
   PubMed Web of Science ®Google Scholar
• KrummelMFAllisonJPCD28 and CTLA-4 have opposing effects on the response of T cells to stimulationJ Exp Med19951824594657543139
   PubMed Web of Science ®Google Scholar
• WillemsenRADebetsRHartEHoogenboomHRBolhuisRLChamesPA phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytesGene Ther200181601160811894998
   PubMed Web of Science ®Google Scholar
• SebestyenZSchootenESalsTHuman TCR that incorporate CD3zeta induce highly preferred pairing between TCRα and β chains following gene transferJ Immunol20081807736774618490778
   PubMed Web of Science ®Google Scholar
• GoversCSebestyénZCoccorisMWillemsenRADebetsRT cell receptor gene therapy: strategies for optimizing transgenic TCR pairingTrends Mol Med201016778720122868
   PubMed Web of Science ®Google Scholar
• RoszikJSebestyenZGoversCT-cell synapse formation depends on antigen recognition but not CD3 interaction: studies with TCR:zeta, a candidate transgene for TCR gene therapyEur J Immunol2011411288129721469084
   PubMedGoogle Scholar
• DenkbergGReiterYRecombinant antibodies with T-cell receptor-like specificity: novel tools to study MHC class I presentationAutoimmun Rev2006525225716697965
   PubMed Web of Science ®Google Scholar
• TorchilinVPMultifunctional, stimuli-sensitive nanoparticulate systems for drug deliveryNat Rev Drug Discov20141381382725287120
   PubMed Web of Science ®Google Scholar
• RigonRBOyafusoMHFujimuraATNanotechnology-based drug delivery systems for melanoma antitumoral therapy: a reviewBiomed Res Int2015841817
   Google Scholar
• LiJWangYLiangRRecent advances in targeted nanoparticles drug delivery to melanomaNanomedicine2015176979425555352
   PubMedGoogle Scholar
• ChenJShaoRZhangXDChenCApplications of nanotechnology for melanoma treatment, diagnosis, and theranosticsInt J Nanomedicine201382677268823926430
   PubMed Web of Science ®Google Scholar
• MaruyamaKOkuizumiaSIshidaaOYamauchibHKikuchibHIwatsuruaMPhosphatidyl polyglycerols prolong liposome circulation in vivoInt J Pharm1994111103107
   Web of Science ®Google Scholar
• TorchilinVPShtilmanMITrubetskoyVSWhitemanKMilsteinAMAmphiphilic vinyl polymers effectively prolong liposome circulation time in vivoBiochim Biophys Acta199411951811847918561
   PubMed Web of Science ®Google Scholar
• TorchilinVPOmelyanenkoVGPapisovMIPoly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevityBiochim Biophys Acta1994119511207918551
   PubMed Web of Science ®Google Scholar
• MaedaHMacromolecular therapeutics in cancer treatment: the EPR effect and beyondJ Control Release201216413814422595146
   PubMed Web of Science ®Google Scholar
• IdenDLAllenTMIn vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approachBiochim Biophys Acta2001151320721611470092
   PubMed Web of Science ®Google Scholar
• AllenTMLigand-targeted therapeutics in anticancer therapyNat Rev Cancer2002275076312360278
   PubMed Web of Science ®Google Scholar
• TorchilinVPImmunoliposomes and PEGylated immunoliposomes: possible use for targeted delivery of imaging agentsImmunomethods199442442587820455
   PubMedGoogle Scholar
• ShmeedaHTzemachDMakLGabizonAHer2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passageJ Control Release200913615516019331844
   PubMed Web of Science ®Google Scholar
• HofmannOCaballeroOLStevensonBJGenome-wide analysis of cancer/testis gene expressionProc Natl Acad Sci U S A2008105204222042719088187
   PubMed Web of Science ®Google Scholar
• ChenYTStockertEChenYIdentification of the MAGE-1 gene product by monoclonal and polyclonal antibodiesProc Natl Acad Sci U S A199491100410088302824
   PubMed Web of Science ®Google Scholar
• De SmetCLurquinCvan der BruggenPDe PlaenEBrasseurFBoonTSequence and expression pattern of the human MAGE2 geneImmunogenetics1994391211298276455
   PubMedGoogle Scholar
• van der BruggenPTraversariCChomezPA gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanomaScience1991254164316471840703
   PubMed Web of Science ®Google Scholar
• LucasSDe PlaenEBoonTMAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: four new members of the MAGE family with tumor-specific expressionInt J Cancer200087556010861452
   PubMed Web of Science ®Google Scholar
• CaballeroOLChenYTCancer/testis (CT) antigens: potential targets for immunotherapyCancer Sci20091002014202119719775
   PubMed Web of Science ®Google Scholar
• ChamesPHuftonSECouliePGUchanska-ZieglerBHoogenboomHRDirect selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab libraryProc Natl Acad Sci U S A2000977969797410884427
   PubMed Web of Science ®Google Scholar
• ChamesPWillemsenRARojasGTCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activityJ Immunol20021691110111812097420
   PubMed Web of Science ®Google Scholar
• DeshpandePPBiswasSTorchilinVPCurrent trends in the use of liposomes for tumor targetingNanomedicine (Lond)201381509152823914966
   PubMed Web of Science ®Google Scholar
• MesserschmidtSKBeuttlerJRothdienerMImmunoliposomesKontermannRDubelSAntibody EngineeringNew York, NYSpringer2010401428
   Google Scholar
• SkerraAPfitzingerIPlückthunAThe functional expression of antibody Fv fragments in Escherichia coli: improved vectors and a generally applicable purification techniqueBiotechnology (N Y)199192732781367302
   PubMedGoogle Scholar
• HochuliELarge-scale chromatography of recombinant proteinsJ Chromatogr19884442933023060478
   PubMed Web of Science ®Google Scholar
• MesserschmidtSKKolbeAMullerDKnollMPleissJKontermannRENovel single-chain Fv’ formats for the generation of immunoliposomes by site-directed couplingBioconjug Chem20081936236917988079
   PubMed Web of Science ®Google Scholar
• BaumPMullerDRugerRKontermannRESingle-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cellsJ Drug Target20071539940617613658
   PubMed Web of Science ®Google Scholar
• RugerRMullerDFahrAKontermannREGeneration of immunoliposomes using recombinant single-chain Fv fragments bound to Ni-NTA-liposomesJ Drug Target20051339940616308208
   PubMed Web of Science ®Google Scholar
• RothdienerMBeuttlerJMesserschmidtSKKontermannREAntibody targeting of nanoparticles to tumor-specific receptors: immunoliposomesMethods Mol Biol201062429530820217604
   PubMedGoogle Scholar
• WillemsenRARonteltapCChamesPDebetsRBolhuisRLT cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine productionJ Immunol20051747853785815944290
   PubMed Web of Science ®Google Scholar
• SchaftNLankiewiczBDrexhageJT cell retargeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNγ productionInt Immunol20061859160116507598
   PubMed Web of Science ®Google Scholar
• AbrahamSAWaterhouseDNMayerLDCullisPRMaddenTDBallyMBThe liposomal formulation of doxorubicinMethods Enzymol2005391719715721375
   PubMed Web of Science ®Google Scholar
• MesserschmidtSKMusyanovychAAltvaterMTargeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cellsJ Control Release2009137697719306900
   PubMed Web of Science ®Google Scholar
• RugerRMullerDFahrAKontermannREIn vitro characterization of binding and stability of single-chain Fv Ni-NTA-liposomesJ Drug Target20061457658217050123
   PubMed Web of Science ®Google Scholar
• MeiLLiuYZhangQGaoHZhangZHeQEnhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicinJ Control Release201419632433125450404
   PubMed Web of Science ®Google Scholar
• RouserGFkeischerSYamamotoATwo dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spotsLipids197054944965483450
   PubMed Web of Science ®Google Scholar
• KontermannREImmunoliposomes for cancer therapyCurr Opin Mol Ther20068394516506524
   PubMed Web of Science ®Google Scholar
• PetersonRCApplication of lowry protein determination to influenza vaccineJ Pharm Sci1969581411425765826
   PubMedGoogle Scholar
• MommaasAMWijsmanMCVerduijnWVermeerBJClaasFMInternalization of MHC class I molecules is a prerequisite for endocytosis of endorphin by lymphocytesClin Exp Immunol1991841701742015708
   PubMedGoogle Scholar
• BanghamADA correlation between surface charge and coagulant action of phospholipidsNature19611921197119813864660
   PubMed Web of Science ®Google Scholar
• SeifertOPollakNNusserAImmuno-LipoTRAIL: targeted delivery of TRAIL-functionalized liposomal nanoparticlesBioconjug Chem20142587988724766622
   PubMed Web of Science ®Google Scholar
• PernisBInternalization of lymphocyte membrane componentsImmunol Today19856454925291392
   PubMedGoogle Scholar
• KoningGAKampsJAScherphofGLEfficient intracellular delivery of 5-fluorodeoxyuridine into colon cancer cells by targeted immunoliposomesCancer Detect Prev20022629930712430634
   PubMedGoogle Scholar
• KoningGAMorseltHWGorterAInteraction of differently designed immunoliposomes with colon cancer cells and Kupffer cells. An in vitro comparisonPharm Res2003201249125712948023
   PubMed Web of Science ®Google Scholar
• ChengWWAllenTMTargeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab’ fragments and single chain FvJ Control Release2008126505818068849
   PubMed Web of Science ®Google Scholar
• MoghimiSMThe effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG liposomesBiomaterials20062713614416019063
   PubMed Web of Science ®Google Scholar
• MareevaTMartinez-HackertESykulevYHow a T cell receptor-like antibody recognizes major histocompatibility complex-bound peptideJ Biol Chem2008283290532905918703505
   PubMedGoogle Scholar
• HulsmeyerMChamesPHilligRCA major histocompatibility complex-peptide-restricted antibody and T cell receptor molecules recognize their target by distinct binding modes: crystal structure of human leukocyte antigen (HLA)-A1-MAGE-A1 in complex with FAB-HYB3J Biol Chem20052802972298015537658
   PubMed Web of Science ®Google Scholar
• LinetteGPStadtmauerEAMausMVCardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanomaBlood201312286387123770775
   PubMed Web of Science ®Google Scholar
• OrenRHod-MarcoMHaus-CohenMFunctional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholdsJ Immunol20141935733574325362181
   PubMed Web of Science ®Google Scholar
• FujimoriKCovellDGFletcherJEWeinsteinJNA modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrierJ Nucl Med199031119111982362198
   PubMed Web of Science ®Google Scholar
• AdamsGPSchierRMcCallAMHigh affinity restricts the localization and tumor penetration of single-chain Fv antibody moleculesCancer Res2001614750475511406547
   PubMed Web of Science ®Google Scholar
• ParsaATWaldronJSPannerALoss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in gliomaNat Med200713848817159987
   PubMed Web of Science ®Google Scholar
• ChenJZhangXDProudCDissecting the signaling pathways that mediate cancer in PTEN and LKB1 double-knockout miceSci Signal20158pe 1
   Google Scholar
• SunMYangCZhengJEnhanced efficacy of chemotherapy for breast cancer stem cells by simultaneous suppression of multidrug resistance and antiapoptotic cellular defenseActa Biomater20152817118226415776
   PubMed Web of Science ®Google Scholar